Real-World Utilization of Daratumumab in Front-Line Treatment of Newly Diagnosed Multiple Myeloma Across a Regional Academic–Community Network
Cancers · 11.06.2026 · 18 (12) · 1899
DOI: 10.3390/cancers18121899 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 11.06.2026. Verfasst von Poy Theprungsirikul und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Section of Hematology and Medical Oncology, Yale School of Medicine, New Haven, CT 06510, USA. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The addition of CD-38 monoclonal antibody daratumumab (DARA) to front-line therapy for newly diagnosed multiple myeloma (NDMM) has improved outcomes. The real-world (RW) adoption of treatments remains inconsistent. We aimed to evaluate the adoption of DARA regimens in the treatment of NDMM.
Methods
We conducted a retrospective study at a multi-site academic–community healthcare system from August 2020–September 2023. Patients (n = 414) were ≥18 years with NDMM upon initiating front-line therapy.
Results
The median age was 69; most were male (60.6%, n = 251), white (69.1%, n = 286), and non-Hispanic (89.6%, n = 371). At diagnosis, 52.2% (n = 216) had R-ISS stage II, and the performance status was preserved, with 69.3% (n = 287) having ECOG 0–1. The adoption of DARA-based induction was incomplete (53.9%, n = 223) and was higher at the academic myeloma center than the community sites (63.9% vs. 47.7%; p = 0.001). At three months after treatment initiation, patients receiving DARA-based induction achieved deeper responses than those treated without DARA. The distribution of IMWG responses favored the DARA group, with a higher proportion attaining VGPR or better (65.0% [n = 145] vs. 51.3% [n = 98]).
Conclusions
DARA-based regimens for NDMM were underutilized and notably less common at community sites. Coordinated implementation strategies at the provider and community levels may narrow adoption gaps and translate trial-proven benefits into routine practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Section of Hematology and Medical Oncology, Yale School of Medicine, New Haven, CT 06510, USA.
- Dana Farber Cancer Institute, Boston, MA 02215, USA.
ORCID-Profile: Amer Al-Musa, Noffar Bar, Sabrina L Browning, Natalia Neparidze
Zitieren
APA
Theprungsirikul, P., Al-Musa, A., Bar, N., Browning, S. L., Parker, T., & Neparidze, N. (2026). Real-World Utilization of Daratumumab in Front-Line Treatment of Newly Diagnosed Multiple Myeloma Across a Regional Academic–Community Network. Cancers, 18(12), 1899. https://doi.org/10.3390/cancers18121899
Vancouver
Theprungsirikul P, Al-Musa A, Bar N, Browning SL, Parker T, Neparidze N. Real-World Utilization of Daratumumab in Front-Line Treatment of Newly Diagnosed Multiple Myeloma Across a Regional Academic–Community Network. Cancers. 2026;18(12):1899. doi:10.3390/cancers18121899
BibTeX
@article{Theprungsirikul2026,
author = {Theprungsirikul, Poy and Al-Musa, Amer and Bar, Noffar and Browning, Sabrina L and Parker, Terri and Neparidze, Natalia},
title = {Real-World Utilization of Daratumumab in Front-Line Treatment of Newly Diagnosed Multiple Myeloma Across a Regional Academic–Community Network},
journal = {Cancers},
year = {2026},
volume = {18},
number = {12},
pages = {1899},
doi = {10.3390/cancers18121899}
}
EUVIMED